Teleflex Q2 2025 Financial Results and Outlook

SEC Filing 8-K (0000096943-25-000112)

Teleflex Incorporated reported its financial results for the second quarter of 2025, ending June 29, 2025. The company announced GAAP revenue of $780.9 million, a 4.2% increase compared to the prior year period. Adjusted constant currency revenue growth was 1.0%. GAAP diluted earnings per share (EPS) from continuing operations were $2.77, compared to $1.69 in the prior year period, while adjusted diluted EPS was $3.73, up from $3.42 in the prior year. Teleflex also raised its full-year 2025 guidance, increasing GAAP revenue growth to a range of 9.00% to 10.00% and adjusted constant currency revenue growth to 7.70% to 8.70%. The company highlighted the acquisition of BIOTRONIK's Vascular Intervention business, which is expected to contribute $204 million in revenue in the second half of 2025. Teleflex continues to focus on its strategic separation into RemainCo and NewCo, with ongoing evaluations for a potential sale of NewCo.